Rare types of breast carcinoma

Steponavičienė, Laura; Gudavičienė, Daiva; Meškauskas, Raimundas

doi:10.6001/actamedica.v19i2.2314

Cited by 5 publications

(14 citation statements)

References 8 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metaplastic carcinomas show a basal like phenotype on immunohistochemistry according to literature. 9 All of our four metaplastic carcinoma cases also showed basal-like phenotype and therefore fall into endocrine nonresponsive category managed by cytotoxic therapy. 7 These tumours maybe associated with recurrences or metastasis.…”

Section: Discussionmentioning

confidence: 73%

“…The mean age of presentation was 54 years similar to the literature. 9 Clinically, all the four females presented with palpable breast lump and axillary lymphadenopathy. Axillary lymph nodes showed benign reactive changes as seen in the literature.…”

Section: Discussionmentioning

confidence: 99%

“…Axillary lymph nodes showed benign reactive changes as seen in the literature. 9 Macroscopically, invasive papillary carcinomas are mostly grossly circumscribed. Resected specimen of one of the case showed a cyst measuring 3 x 3 cm with an intracystic papillary projection.…”

Section: Discussionmentioning

confidence: 99%

“…7 Metaplastic carcinoma refers to a heterogeneous group of the neoplasms characterised by admixture of adenocarcinoma with dominant areas of spindle cell, squamous and/or mesenchymal differentiation. 9 The WHO classifies metaplastic carcinoma into two types, epithelial and mixed type. 10 They constitute less than 1% of all the invasive breast carcinomas and commonly diagnosed in women more than 50 years of age.…”

Section: Discussionmentioning

confidence: 99%

“…Metaplastic carcinoma is usually diagnosed with T2 disease with a mean size 3.4-4.4 cm. 9 In the present study, we received four cases of metaplastic carcinoma with similar clinicopathologic features. Metaplastic carcinomas show a basal like phenotype on immunohistochemistry according to literature.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Immunohistochemistry as Surrogate Marker for Molecular Typing of Special Types of Breast Carcinomas

Mekhala¹,

Aruna²,

N³

et al. 2016

jebmh

View full text Add to dashboard Cite

BACKGROUNDBreast cancer is a heterogeneous disease with variable morphological features, clinical outcomes and response to different therapeutic options. Gene expression profiling studies on breast carcinomas have revolutionised the classification of breast carcinomas into molecular subtypes enhancing the treatment protocols and offering better prediction of outcomes. MATERIALS AND METHODSThe present study aims to discuss the special histological variants with special emphasis on their molecular phenotype using surrogate immunohistochemical markers. RESULTSSpecial variants of breast carcinomas diagnosed during the study period of two years from August 2013 and July 2015 were classified into molecular subtypes using immunohistochemical expression of ER, PR and HER-2. CONCLUSIONSSpecial types of breast carcinomas are very rare and have different clinicopathologic behaviours. It is important to know their characteristics to make proper management decisions and to predict the prognosis. KEYWORDSIHC, Molecular Typing of Breast Carcinomas, Special Types of Breast Cancers. HOW TO CITE THIS ARTICLE: Mekhala PM, Aruna L, Arasi NE, et al. Immunohistochemistry as surrogate marker for molecular typing of special types of breast carcinomas.

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Immunohistochemistry as Surrogate Marker for Molecular Typing of Special Types of Breast Carcinomas

Mekhala¹,

Aruna²,

N³

et al. 2016

jebmh

View full text Add to dashboard Cite

show abstract

Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US

et al. 2021

View full text Add to dashboard Cite

IMPORTANCE Triple-negative breast cancers are known collectively to demonstrate a more aggressive clinical course and earlier recurrence than cancers of other histological subtypes.However, the literature on rare triple-negative breast cancers and the association of histological type with survival and risk of metastasis is sparse.OBJECTIVE To present the clinical and demographic characteristics, treatment patterns, and overall survival (OS) for histologically rare (<10% of breast cancers) triple-negative breast cancer types: medullary carcinoma, adenoid cystic carcinoma, and metaplastic breast carcinoma. DESIGN, SETTING, AND PARTICIPANTSThis cohort study was performed in the US using data reported by the National Cancer Database between 2010 and 2016. Confirmed cases of medullary carcinoma, adenoid cystic carcinoma, and metaplastic breast cancer were analyzed. Univariable analyses and multivariable Cox regression models were performed. Data analysis was performed from April to May 2020. MAIN OUTCOMES AND MEASURES The primary outcome was 5-year OS. Secondary outcomes included site of metastasis, effect of immunohistochemistry, management, and 2-year mortality. RESULTS A total of 8479 patients with breast cancer (mean [SD] age; 62.6 [14.3] years; 8435 women [99.48%]) were analyzed. Metaplastic carcinoma was the most commonly diagnosed histological type in this cohort, with 6867 patients (81%), followed by 1357 (16%) with adenoid cystic carcinoma and only 255 (3%) with medullary carcinoma. Medullary carcinoma presented earlier in life, at a median (interquartile range) age of 53 (45-62) years, compared with 62 (53-72) years for patients with adenoid cystic carcinoma and 63 (52-74) years for patients with metaplastic carcinoma. The proportion of tumors with triple-negative immunohistochemistry varied by histological type for medullary carcinoma (57 patients [22.4%]), adenoid cystic carcinoma (653 patients [48.1%]), and metaplastic carcinoma (3637 patients [53.0%]). Patients with adenoid cystic carcinoma were less likely to receive radiotherapy (711 patients [52.4%]) and chemotherapy (175 patients [12.9%]) compared with patients with medullary carcinoma (radiotherapy, 156 patients [61.2%]; chemotherapy, 190 patients [74.5%]) and metaplastic carcinoma (radiotherapy, 3416 patients [49.7%]; chemotherapy, 4709 patients [68.6%]). The 5-year OS rate was superior for patients with medullary (91.7%) and adenoid cystic carcinoma (88.4%) compared with patients with metaplastic carcinoma (63.1%). The 5-year mortality rate for adenoid cystic carcinoma was 8.33% vs 36.91% for metaplastic carcinoma. CONCLUSIONS AND RELEVANCENationally, over the course of 7 years, medullary carcinoma was most common and metaplastic carcinoma had the worst 5-year OS among the rare histological breast cancer subtypes analyzed. Factors associated with a poor prognosis for metaplastic carcinoma included advanced stage, lung metastasis, older age, and not receiving chemotherapy or radiation (continued) Key Points Question Do all triple-negative breast ca...

show abstract

Unusual Breast Neoplasm with Diagnostic and Management Challenges

Rana

Ramakant

Babu

et al. 2018

Indian J Surg Oncol

View full text Add to dashboard Cite

With the growing awareness and availability of proper screening methods, detection of breast lump is increasing globally and is now a very sensitive issue for females. The treatment of these lumps ranges from lumpectomy to wide local excision to mastectomy; hence, a proper diagnosis is very important to prevent under-or overtreatment in patients. Breast lesions are the heterogeneous diseases encompassing several distinct entities with remarkably different characteristics. While the more common forms of breast cancers are well recognized and understood better, there are many important unusual lesions and malignancies that are less known and less appreciated and can be challenging to diagnose. In such cases, due to rarity of the disease and lack of adequate treatment protocol, managing the patients can be a challenging task for surgeons and oncologist as well. In this article, we have shared our institutional experience in unusual breast lesions with emphasis on diagnostic as well as management challenges faced.

show abstract

Rare types of breast carcinoma

Cited by 5 publications

References 8 publications

Immunohistochemistry as Surrogate Marker for Molecular Typing of Special Types of Breast Carcinomas

Immunohistochemistry as Surrogate Marker for Molecular Typing of Special Types of Breast Carcinomas

Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US

Unusual Breast Neoplasm with Diagnostic and Management Challenges

Contact Info

Product

Resources

About